- Home
- TMC vs FATE Comparison
TMC vs FATE Comparison
Compare TMC & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TMC
- FATE
- Stock Information
- Founded
- TMC 2011
- FATE 2007
- Country
- TMC Canada
- FATE United States
- Employees
- TMC N/A
- FATE N/A
- Industry
- TMC Metal Mining
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TMC Basic Materials
- FATE Health Care
- Exchange
- TMC Nasdaq
- FATE Nasdaq
- Market Cap
- TMC N/A
- FATE 177.7M
- IPO Year
- TMC N/A
- FATE 2013
- Fundamental
- Price
- TMC $7.57
- FATE $1.13
- Analyst Decision
- TMC Strong Buy
- FATE Hold
- Analyst Count
- TMC 3
- FATE 7
- Target Price
- TMC $6.75
- FATE $3.83
- AVG Volume (30 Days)
- TMC 15.5M
- FATE 1.6M
- Earning Date
- TMC 08-13-2025
- FATE 08-12-2025
- Dividend Yield
- TMC N/A
- FATE N/A
- EPS Growth
- TMC N/A
- FATE N/A
- EPS
- TMC N/A
- FATE N/A
- Revenue
- TMC N/A
- FATE $13,335,000.00
- Revenue This Year
- TMC N/A
- FATE N/A
- Revenue Next Year
- TMC N/A
- FATE N/A
- P/E Ratio
- TMC N/A
- FATE N/A
- Revenue Growth
- TMC N/A
- FATE 105.85
- 52 Week Low
- TMC $0.72
- FATE $0.66
- 52 Week High
- TMC $8.12
- FATE $5.92
- Technical
- Relative Strength Index (RSI)
- TMC 64.32
- FATE 46.21
- Support Level
- TMC $6.33
- FATE $1.12
- Resistance Level
- TMC $7.25
- FATE $1.18
- Average True Range (ATR)
- TMC 0.63
- FATE 0.07
- MACD
- TMC -0.02
- FATE 0.00
- Stochastic Oscillator
- TMC 76.15
- FATE 55.00
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.